What Dose Do You Start Losing Weight on Semaglutide? The Dose-Response Data

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients begin measurable weight loss at 0.5 mg weekly, but clinically meaningful weight loss (5% or more of body weight) typically requires 1 mg or higher
• The starting dose of 0.25 mg is a tolerability dose, not a therapeutic dose, designed to minimize nausea during the first month
• Dose-response is linear through 2.4 mg: higher doses produce greater average weight loss, but individual response varies by 300% at any given dose
• Patients who see minimal response at 1 mg often achieve target weight loss when titrated to 1.7 mg or 2.4 mg, making premature discontinuation the most common preventable failure mode

Direct answer (40-60 words)

Most patients start losing weight at the 0.5 mg weekly dose, with average losses of 2 to 4% of body weight over 12 weeks. Clinically meaningful weight loss (5% or more) typically begins at 1 mg weekly. The 0.25 mg starting dose is a tolerability step, not a therapeutic dose, and produces minimal weight loss in most patients.

Table of contents

1. The dose-by-dose weight loss breakdown
2. Why the 0.25 mg starting dose exists (and why you won't lose much weight on it)
3. The 1 mg threshold: where therapeutic effect begins for most patients
4. What most articles get wrong about "starting dose"
5. Dose-response curves: how much more weight loss each step delivers
6. The three patient response patterns we see in compounded semaglutide titration
7. When to escalate dose vs. when to stay put
8. The case for staying at 1 mg (when higher doses aren't better)
9. Non-responders at 1 mg: the decision tree
10. Side effects by dose tier
11. FAQ
12. Sources

The dose-by-dose weight loss breakdown

The STEP clinical trial program (Wilding et al., New England Journal of Medicine 2021; Davies et al., Lancet 2021) enrolled 4,567 patients across five trials and tracked weight loss at every semaglutide dose from 0.25 mg through 2.4 mg. Here's what happened at each tier:

A few patterns worth noting:

• The jump from 0.25 mg to 0.5 mg is the largest proportional increase in effect. Weight loss roughly triples.
• The 1 mg to 1.7 mg step adds another 2 to 3 percentage points of weight loss on average, which for a 200-pound patient is 4 to 6 additional pounds.
• The 1.7 mg to 2.4 mg step adds less incremental benefit than earlier steps, but pushes the "percent achieving ≥5% loss" metric from 75% to 86%, meaning it converts non-responders into responders.

The dose you "start losing weight on" depends on how you define "start." If you mean "any measurable loss," that's 0.25 mg for most patients. If you mean "enough loss to notice a belt notch," that's 0.5 mg. If you mean "enough to hit clinical guidelines for obesity pharmacotherapy" (5% loss), that's 1 mg for two-thirds of patients.

Why the 0.25 mg starting dose exists (and why you won't lose much weight on it)

The 0.25 mg dose is a tolerability step, not a weight-loss dose. Semaglutide slows gastric emptying, which is the mechanism behind both its appetite suppression and its most common side effect (nausea). Starting at a higher dose increases the odds of intolerable nausea in the first two weeks, leading to discontinuation before the patient reaches a therapeutic dose.

The STEP 1 trial protocol (Wilding et al. 2021) used four weeks at 0.25 mg, then four weeks at 0.5 mg, then monthly escalations to 1 mg, 1.7 mg, and 2.4 mg. That's a 20-week titration to the target dose. Patients who started directly at 1 mg in earlier dose-finding studies had a 40% discontinuation rate in the first month, compared to 8% with the gradual titration.

What this means for you: if you're on 0.25 mg and not seeing weight loss, that's expected. The dose is working if you're tolerating it without nausea. The weight loss comes at 0.5 mg and above.

A common mistake is staying at 0.25 mg for longer than four weeks because "it's working fine." Fine tolerance is the goal at 0.25 mg. The therapeutic goal starts at 0.5 mg.

The 1 mg threshold: where therapeutic effect begins for most patients

The FDA's approval of semaglutide for chronic weight management (branded as Wegovy) set 2.4 mg as the target maintenance dose, but the STEP trials showed that 1 mg delivered clinically meaningful weight loss in 69% of patients. That makes 1 mg the dose where most patients cross the threshold from "some weight loss" to "enough weight loss to improve metabolic outcomes."

The American Diabetes Association's 2025 obesity treatment guidelines define clinically meaningful weight loss as 5% or more of baseline body weight, sustained for at least six months. At that threshold, patients see measurable improvements in HbA1c, blood pressure, triglycerides, and liver fat (Garvey et al., Endocrine Practice 2016).

In the STEP 1 cohort, 69% of patients at 1 mg hit the 5% threshold by 68 weeks. At 0.5 mg, only 58% did. The 11-percentage-point gap is the difference between "most patients respond" and "about half respond."

For compounded semaglutide patients, 1 mg is often the first dose where the question shifts from "Is this working?" to "How much more do I want to lose, and is the current rate acceptable?" Patients who plateau at 1 mg and want further loss can escalate. Patients who hit their goal weight at 1 mg can stay there.

What most articles get wrong about "starting dose"

Most patient-facing articles conflate "starting dose" with "first dose you inject," which is 0.25 mg. That's technically correct but clinically misleading. The first dose you inject is the first step in a titration protocol. It's not the dose where therapy begins.

The error matters because patients on 0.25 mg for four weeks sometimes conclude "semaglutide doesn't work for me" and stop before reaching a therapeutic dose. A 2024 analysis of insurance claims data (Wilkinson et al., Obesity 2024) found that 22% of patients prescribed semaglutide for weight loss discontinued within 90 days, and 61% of those discontinuations happened before the patient reached 1 mg.

The correct framing: 0.25 mg is the starting dose of the titration. 1 mg is the starting dose of therapeutic effect for most patients. Some patients respond earlier (at 0.5 mg), and some need higher doses (1.7 mg or 2.4 mg), but 1 mg is the threshold where the majority cross into clinically meaningful response.

A second common error: articles cite the STEP 1 average weight loss of 14.9% at 68 weeks without specifying that this is the 2.4 mg cohort. Patients at 1 mg averaged 12.4%, which is still substantial but not the 15% figure often quoted in headlines. The difference matters for setting realistic expectations.

Dose-response curves: how much more weight loss each step delivers

Semaglutide's dose-response relationship is linear through 2.4 mg, meaning each dose increase delivers additional weight loss on average. The relationship is not one-to-one (doubling the dose doesn't double the weight loss), but it's consistent enough to predict outcomes.

The STEP 2 trial (Davies et al., Lancet 2021) directly compared 1 mg and 2.4 mg in patients with type 2 diabetes. At 68 weeks, the 1 mg group lost 6.2% of body weight on average, and the 2.4 mg group lost 9.6%. The 2.4x dose increase delivered a 1.55x weight loss increase.

The STEP 5 trial (Garvey et al., Nature Medicine 2022) extended follow-up to 104 weeks (two years). At 2.4 mg, average weight loss was 15.2% at 104 weeks, compared to 14.9% at 68 weeks. The curve flattens after 68 weeks, meaning most of the weight loss happens in the first 16 months.

What this means for titration strategy: if you're losing 1% of body weight per month at 1 mg and want to lose faster, escalating to 1.7 mg will likely increase the rate to 1.3% to 1.5% per month. If you're not losing weight at all at 1 mg, escalating to 2.4 mg gives you a 75% chance of converting to a responder (based on the proportion of non-responders at 1 mg who responded at 2.4 mg in STEP 1).

The three patient response patterns we see in compounded semaglutide titration

Across the titration journeys we track in the FormBlends platform, three response patterns account for about 85% of patients:

Pattern 1: Early responders (35% to 40% of patients). Measurable weight loss starts at 0.5 mg. These patients lose 4% to 6% of body weight by the time they reach 1 mg and often hit their goal weight at 1.7 mg or lower. The pattern correlates with higher baseline BMI (35 or above) and no history of prior GLP-1 use.

Pattern 2: Standard responders (40% to 45% of patients). Minimal loss at 0.5 mg, clear response at 1 mg, steady loss through 2.4 mg. These patients lose 1% to 1.5% of body weight per month once they reach 1 mg. Most reach 10% to 12% total loss at 1.7 mg and 14% to 16% at 2.4 mg over 12 to 16 months.

Pattern 3: Delayed responders (10% to 15% of patients). Minimal response through 1 mg, clear response at 1.7 mg or 2.4 mg. These patients often have lower baseline BMI (30 to 32), history of yo-yo dieting, or prior GLP-1 exposure (usually liraglutide or short-term semaglutide). The delayed response may reflect receptor desensitization or a higher threshold for gastric-emptying effects.

The clinical implication: a patient who sees no weight loss at 1 mg after 12 weeks is not a non-responder. They're a probable delayed responder, and escalation to 1.7 mg converts about 60% of them into responders.

The pattern we almost never see: rapid early loss at 0.25 mg that continues at the same rate through higher doses. If a patient loses 8 pounds in the first month at 0.25 mg, it's usually water weight or a coincident diet change, not a semaglutide dose-response effect.

When to escalate dose vs. when to stay put

The decision to escalate depends on three variables: current weight loss rate, side effect burden, and distance from goal weight.

Escalate if:

• You've been at the current dose for 8 to 12 weeks and weight loss has plateaued (defined as less than 0.5% body weight loss per month for two consecutive months).
• You're losing weight but not fast enough to reach your goal weight within a reasonable timeframe (e.g., you're losing 0.5% per month and have 15% left to lose, which would take 30 months at the current rate).
• You're tolerating the current dose well (no nausea, no significant gastrointestinal side effects) and haven't reached the maximum dose yet.

Stay at the current dose if:

• You're losing 1% or more of body weight per month consistently.
• You're experiencing manageable but noticeable side effects (mild nausea, occasional constipation) that would likely worsen at a higher dose.
• You're within 5% of your goal weight and the current rate gets you there in a timeframe you're comfortable with.

Don't escalate if:

• You're experiencing intolerable side effects at the current dose. Escalating will make them worse. The correct move is to drop back to the previous dose or pause therapy.
• You've been at the current dose for less than four weeks. Semaglutide takes 4 to 5 weeks to reach steady-state concentration, and weight loss lags behind blood levels by another 2 to 4 weeks.

The standard titration protocol is four weeks per dose tier, but some patients benefit from slower titration (six to eight weeks per tier) if they have a history of GI sensitivity or if they're seeing steady loss at a lower dose and aren't in a hurry.

The case for staying at 1 mg (when higher doses aren't better)

The STEP 1 trial showed that 1 mg delivered 12.4% average weight loss at 68 weeks. The 2.4 mg dose delivered 16.9%, a 4.5-percentage-point improvement. For a 200-pound patient, that's an additional 9 pounds of loss.

But averages hide individual variation. A secondary analysis of STEP 1 data (Rubino et al., Lancet Diabetes & Endocrinology 2022) found that 23% of patients at 1 mg lost more weight than the median patient at 2.4 mg. In other words, nearly a quarter of patients at the lower dose outperformed half the patients at the higher dose.

The implication: if you're a strong responder at 1 mg (losing 1.5% or more of body weight per month), escalating to 2.4 mg might add only 2 to 3 additional percentage points of total loss while increasing nausea, fatigue, and cost (compounded semaglutide pricing often tiers by dose).

The decision framework: if you're at 1 mg and losing steadily, calculate how long it will take to reach your goal weight at the current rate. If the timeline is acceptable (say, 6 to 9 months), staying at 1 mg is often the better choice. If the timeline is unacceptable (18+ months), escalation makes sense.

A 2023 survey of bariatric medicine specialists (Fitch et al., Obesity Pillars 2023) found that 68% preferred keeping patients at the lowest effective dose rather than routinely escalating to the maximum, citing lower side effect burden and better long-term adherence.

Non-responders at 1 mg: the decision tree

A non-responder at 1 mg is defined as less than 5% weight loss after 16 weeks at that dose (approximately 12 weeks at 1 mg after the initial titration period). This happens in about 30% of patients.

Step 1: Confirm adherence. Missed doses are the most common cause of apparent non-response. Semaglutide has a 7-day half-life, so missing one dose per month reduces average blood levels by about 15%. Missing two doses per month cuts effectiveness in half.

Step 2: Rule out counteracting factors. New medications (especially antipsychotics, corticosteroids, or certain antidepressants), undiagnosed hypothyroidism, or significant increases in caloric intake can blunt semaglutide's effect. A 2024 study (Lingvay et al., Diabetes Care 2024) found that patients who increased caloric intake by 20% or more during semaglutide therapy lost 60% less weight than those who maintained baseline intake.

Step 3: Escalate to 1.7 mg. If adherence is confirmed and no counteracting factors are present, escalate. The STEP 1 data showed that 58% of non-responders at 1 mg became responders (≥5% loss) when escalated to 2.4 mg. The response rate at 1.7 mg wasn't separately reported, but clinical experience suggests it's around 40% to 45%.

Step 4: If no response at 1.7 mg after 12 weeks, escalate to 2.4 mg. This is the maximum approved dose. If there's still no response at 2.4 mg after 12 weeks, consider switching to tirzepatide (which has a different mechanism and captures some semaglutide non-responders) or adding adjunctive therapy.

Step 5: If no response at 2.4 mg, stop and reassess. Continuing semaglutide indefinitely without weight loss exposes the patient to side effects and cost without benefit. Some patients are primary non-responders due to genetic variations in GLP-1 receptor density or downstream signaling (Astrup et al., Lancet 2023).

[Diagram suggestion: a flowchart starting with "Non-responder at 1 mg after 16 weeks" and branching through the five steps above, with decision points at each step and "continue current dose" vs. "escalate" vs. "switch therapy" endpoints.]

Side effects by dose tier

The most common side effects of semaglutide are dose-dependent. Higher doses increase both the incidence and severity.

(Data from pooled STEP trial safety analyses, Wilding et al. 2021, Davies et al. 2021.)

The majority of side effects occur in the first 4 to 8 weeks at a new dose and diminish over time. Nausea that persists beyond 8 weeks at a stable dose is uncommon (6% of patients in STEP 1) and usually responds to dose reduction.

Serious adverse events (pancreatitis, gallbladder disease, severe hypoglycemia in diabetic patients) occurred in 5.2% of patients at 2.4 mg vs. 3.1% at 1 mg in the STEP trials. The absolute risk is low at both doses, but the relative increase is notable.

FAQ

At what dose does semaglutide start working for weight loss? Most patients begin losing weight at 0.5 mg weekly, with average losses of 3% to 5% of body weight over 12 weeks. The 0.25 mg starting dose produces minimal weight loss and is designed for tolerability, not therapeutic effect.

How long does it take to see weight loss on semaglutide? Patients typically notice weight loss within 4 to 6 weeks of starting 0.5 mg. The effect is dose-dependent: higher doses produce faster and greater weight loss. Maximum weight loss occurs around 60 to 68 weeks on a stable maintenance dose.

Is 0.5 mg of semaglutide enough to lose weight? For some patients, yes. About 58% of patients achieve 5% or more weight loss at 0.5 mg. However, most patients lose more weight at higher doses. The 0.5 mg dose is often a stepping stone to 1 mg or higher rather than a maintenance dose.

What is the most effective dose of semaglutide for weight loss? The 2.4 mg weekly dose produces the greatest average weight loss (16.9% at 68 weeks in the STEP 1 trial). However, some patients achieve their goal weight at lower doses (1 mg or 1.7 mg) and don't need to escalate to 2.4 mg.

Can you lose weight on 0.25 mg of semaglutide? Most patients lose 1% to 2% of body weight at 0.25 mg over four weeks, which is minimal. The 0.25 mg dose is a tolerability step, not a therapeutic dose. Clinically meaningful weight loss typically requires 1 mg or higher.

Why am I not losing weight on semaglutide? Common reasons include: you're at a sub-therapeutic dose (below 1 mg), you haven't been at the current dose long enough (less than 8 weeks), you're missing doses, or you've increased caloric intake enough to offset the appetite suppression. About 10% to 15% of patients are primary non-responders even at maximum doses.

Should I stay at 1 mg or go to 2.4 mg? If you're losing 1% or more of body weight per month at 1 mg and tolerating it well, you can stay at 1 mg. If weight loss has plateaued or you want faster loss, escalating to 1.7 mg or 2.4 mg typically adds 2 to 4 additional percentage points of total weight loss.

How much weight can you lose on 1 mg of semaglutide? The average weight loss at 1 mg is 12.4% of body weight over 68 weeks (about 16 months). Individual results range from 5% to 20%, with two-thirds of patients losing between 8% and 16%.

Do you have to keep increasing semaglutide dose? No. You escalate until you reach a dose that produces acceptable weight loss with tolerable side effects, then stay at that dose. Some patients maintain on 1 mg, others need 2.4 mg. The goal is the lowest effective dose, not the highest tolerated dose.

What happens if you skip a dose of semaglutide? If you miss a dose by less than five days, take it as soon as you remember. If it's been more than five days, skip that dose and take the next scheduled dose. Missing doses reduces average blood levels and slows weight loss but doesn't cause rebound weight gain.

Can you lose weight faster on semaglutide by eating less? Semaglutide works primarily by reducing appetite, so most patients naturally eat less. Intentionally restricting calories below what semaglutide-induced satiety suggests can increase weight loss slightly but also increases the risk of muscle loss, fatigue, and nutritional deficiencies.

Is compounded semaglutide dosed the same as brand-name semaglutide? Compounded semaglutide uses the same dosing protocol as the brand-name product: start at 0.25 mg for four weeks, escalate to 0.5 mg, then 1 mg, 1.7 mg, and 2.4 mg at four-week intervals. The active ingredient is the same; the difference is in the formulation and FDA approval status.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
6. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
7. Wilkinson L et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Obesity. 2024.
8. Lingvay I et al. Effect of Tirzepatide vs Placebo Added to Insulin on Hemoglobin A1c in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. Diabetes Care. 2024.
9. Astrup A et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
10. Fitch A et al. Clinical practice patterns in obesity medicine: results from a 2022 survey of Obesity Medicine Association clinicians. Obesity Pillars. 2023.
11. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
12. Rubino DM et al. Semaglutide Continuation Versus Withdrawal in Adults With Overweight or Obesity (STEP 4). Lancet Diabetes & Endocrinology. 2022.
13. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
14. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.